12.1 Severe Community & Hospital-Acquired Infections in the ED

12.1 Severe Community & Hospital-Acquired Infections in the ED

Sepsis & Septic Shock: SSC 1-Hour Bundle & Antimicrobial Timing

In the emergency department, sepsis is defined as life-threatening organ dysfunction caused by a dysregulated host response to infection. Clinically, organ dysfunction is quantified by an acute increase in the Sequential Organ Failure Assessment (SOFA) score of ≥2 points. In the rapid triage setting, the quick SOFA (qSOFA) criteria (respiratory rate ≥22 breaths/min, altered mentation with Glasgow Coma Scale <15, and systolic blood pressure ≤100 mmHg) identify patients at high risk of rapid deterioration.

Septic shock represents a subset of sepsis in which underlying circulatory and cellular metabolism abnormalities are profound enough to substantially increase mortality. It is clinically recognized by persistent hypotension requiring vasopressors to maintain a mean arterial pressure (MAP) ≥65 mmHg and a serum lactate >2 mmol/L (18 mg/dL) despite adequate crystalloid fluid resuscitation (30 mL/kg within 3 hours).

Surviving Sepsis Campaign (SSC) 1-Hour Bundle

The Surviving Sepsis Campaign guidelines establish clear operational timelines for antimicrobial administration:

1. Definite or High-Likelihood Sepsis / Septic Shock: Administer empiric broad-spectrum intravenous antimicrobials immediately, ideally within 1 hour of recognition.
2. Possible Sepsis Without Shock: Rapidly conduct a diagnostic assessment of infectious versus non-infectious etiologies and administer antimicrobials within 3 hours if concern for infection persists.
3. Blood Cultures Prior to Antibiotics: Obtain two sets of blood cultures (aerobic and anaerobic bottles from distinct venipuncture sites) prior to antimicrobial administration, provided culture collection does not delay antimicrobial infusion beyond 45 minutes.

---

Community-Acquired Pneumonia (CAP): Inpatient Severe ICU Stratification

Community-Acquired Pneumonia (CAP) remains a leading cause of ED admission and septic shock. While outpatient CAP is treated with narrow-spectrum agents (high-dose amoxicillin, doxycycline, or amoxicillin-clavulanate plus a macrolide), patients requiring hospitalization must be stratified by illness severity.

ATS/IDSA Severe CAP Criteria

Severe CAP requiring admission to an intensive care unit (ICU) is defined by the presence of at least 1 major criterion OR at least 3 minor criteria:

• Major Criteria:
  • Septic shock requiring vasopressor support
  • Respiratory failure requiring invasive mechanical ventilation
• Minor Criteria:
  • Respiratory rate ≥30 breaths/min
  • PaO2/FiO2 ratio ≤250
  • Multilobar infiltrates on chest imaging
  • Confusion or disorientation
  • Uremia (blood urea nitrogen [BUN] ≥20 mg/dL)
  • Leukopenia (white blood cell count <4,000 cells/mcL)
  • Thrombocytopenia (platelet count <100,000/mcL)
  • Hypothermia (core temperature <36.0°C)
  • Hypotension requiring aggressive fluid resuscitation

Empiric Regimens for Severe ICU CAP

Patients meeting severe CAP criteria require mandatory dual therapy covering Streptococcus pneumoniae, Legionella pneumophila, Haemophilus influenzae, and atypical respiratory pathogens.

• Standard Severe ICU CAP Regimen:
  • Ceftriaxone 1 g to 2 g IV every 24 hours (or Ampicillin-sulbactam 3 g IV every 6 hours) PLUS
  • Azithromycin 500 mg IV every 24 hours OR Levofloxacin 750 mg IV every 24 hours
• Risk Factors for MRSA or Pseudomonas aeruginosa:
  • The ATS/IDSA CAP guidelines removed the prior Healthcare-Associated Pneumonia (HCAP) categorization. Empiric MRSA and antipseudomonal agents are not routinely indicated for all severe CAP patients. They are reserved strictly for patients with:
    1. Prior respiratory isolation of MRSA or P. aeruginosa (within the preceding 12 months), OR
    2. Recent hospitalization and parenteral antibiotic exposure within the preceding 90 days, accompanied by locally validated risk factors.
• Modified Regimen When Risk Factors Present:
  • Substitute Ceftriaxone with Cefepime 2 g IV every 8 hours (extended infusion) or Piperacillin-tazobactam 4.5 g IV every 6 hours (extended infusion) PLUS
  • Add Vancomycin 15-20 mg/kg IV every 8-12 hours (targeting an AUC/MIC of 400-600) or Linezolid 600 mg IV every 12 hours PLUS
  • Add Levofloxacin 750 mg IV daily or Azithromycin 500 mg IV daily.
  • Obtain a rapid nasal MRSA PCR screen in the ED; a negative nasal swab provides a negative predictive value >95-99%, facilitating prompt discontinuation of vancomycin or linezolid within 24-48 hours.

---

Hospital-Acquired & Ventilator-Associated Pneumonia (HAP/VAP)

Hospital-Acquired Pneumonia (HAP) is defined as pneumonia developing ≥48 hours after hospital admission that was not incubating at presentation. Ventilator-Associated Pneumonia (VAP) arises >48 hours following endotracheal intubation. In the ED, clinicians frequently encounter HAP in patients boarding during hospital overcrowding or transferring from long-term acute care facilities.

Risk Factors for Multidrug-Resistant (MDR) Pathogens

• Prior intravenous antimicrobial use within the preceding 90 days
• Septic shock at the time of HAP or VAP presentation
• Acute respiratory distress syndrome (ARDS) preceding VAP
• Five or more days of hospitalization prior to the onset of VAP
• Acute renal replacement therapy required prior to VAP onset

Empiric Regimen Construction

When treating patients with severe HAP or VAP with high risk of MDR pathogens or high local mortality risk, guidelines dictate triple empiric coverage: two antipseudomonal agents from different mechanistic classes plus one agent active against MRSA.

---

Acute Bacterial Meningitis: Rapid Assessment & High-Dose Regimens

Acute bacterial meningitis is an immediate neurological and infectious emergency. The classic clinical presentation includes fever, altered mental status, and nuchal rigidity (present in >95% of patients having at least two of these signs). In the ED, lumbar puncture (LP) must be performed urgently. However, antimicrobial therapy must never be delayed for neuroimaging or LP completion.

Indications for Head CT Prior to Lumbar Puncture

If any of the following clinical features are present, draw blood cultures immediately, administer adjunctive dexamethasone and empiric antimicrobials, and then obtain a non-contrast head CT to rule out intracranial mass effect or impending brain herniation before attempting LP:

• Immunocompromised state (HIV/AIDS, immunosuppressive therapy, post-transplantation)
• History of central nervous system (CNS) disease (mass lesion, stroke, focal infection)
• New-onset seizure within 1 week of presentation
• Papilledema on fundoscopic examination
• Abnormal level of consciousness (Glasgow Coma Scale score <10)
• Focal neurological deficit (e.g., cranial nerve palsy, hemiparesis, visual field defect)

Pathogen Stratification & High-Dose Regimens

Because the blood-brain barrier severely restricts antibiotic penetration, high doses are mandatory to achieve bactericidal concentrations in the cerebrospinal fluid (CSF):

• Age 2 to 49 Years:
  • Pathogens: Streptococcus pneumoniae, Neisseria meningitidis
  • Regimen: Ceftriaxone 2 g IV every 12 hours PLUS Vancomycin 15-20 mg/kg IV every 8 to 12 hours
• Age ≥50 Years OR Immunocompromised OR Alcohol Use Disorder:
  • Pathogens: S. pneumoniae, N. meningitidis, Listeria monocytogenes, aerobic Gram-negative bacilli
  • Regimen: Ceftriaxone 2 g IV every 12 hours PLUS Vancomycin 15-20 mg/kg IV every 8 to 12 hours PLUS Ampicillin 2 g IV every 4 hours

                    ACUTE BACTERIAL MENINGITIS DECISION ALGORITHM
  ┌─────────────────────────────────────────────────────────────────────────────┐
  │ Clinical Suspicion: Fever, Neck Stiffness, Altered Sensorium, Headache      │
  └──────────────────────────────────────┬──────────────────────────────────────┘
                                         ▼
                  Check for CT Indication Before Lumbar Puncture:
         [Focal Neuro Deficit | Seizure | Papilledema | GCS < 10 | Immunocompromised]
                                         │
                 ┌───────────────────────┴───────────────────────┐
                 ▼ YES                                           ▼ NO
  ┌───────────────────────────────┐              ┌───────────────────────────────┐
  │ 1. Draw Blood Cultures x 2    │              │ 1. Perform Immediate LP       │
  │ 2. Dexamethasone 10 mg IV     │              │ 2. Dexamethasone 10 mg IV     │
  │ 3. Ceftriaxone 2g + Vanc +    │              │ 3. Ceftriaxone 2g + Vanc +    │
  │    Ampicillin (if age >= 50)  │              │    Ampicillin (if age >= 50)  │
  │ 4. Send for Urgent Head CT    │              │ 4. Send CSF for Diagnostics   │
  └───────────────────────────────┘              └───────────────────────────────┘

Adjunctive Dexamethasone Pharmacology

• Dose & Route: 10 mg IV every 6 hours for 4 days (pediatric 0.15 mg/kg every 6 hours).
• Timing: Administer 10 to 20 minutes prior to, or at the latest concurrently with, the first dose of antimicrobial therapy.
• Pharmacologic Rationale: Rapid bacterial lysis induced by bactericidal beta-lactam antibiotics releases large quantities of cell wall degradation products (teichoic acid, peptidoglycan fragments, pneumolysin, and endotoxins) into the subarachnoid space. This triggers a massive microglial inflammatory burst, release of IL-1beta and TNF-alpha, cerebral edema, elevated intracranial pressure, and neuronal apoptosis. Pre-treatment with dexamethasone dampens this inflammatory surge.
• Clinical Benefit: Significantly reduces mortality and sensorineural hearing loss, specifically in adult Streptococcus pneumoniae meningitis (and Haemophilus influenzae type b in pediatric populations). If given after antibiotics, corticosteroids lose their protective efficacy. Dexamethasone should be discontinued if CSF culture or PCR reveals an organism other than S. pneumoniae.
• The Listeria Dilemma: Listeria monocytogenes possesses altered penicillin-binding proteins with low binding affinity for all cephalosporins. Ceftriaxone, cefepime, and all other cephalosporins have zero clinical activity against Listeria. Ampicillin 2 g IV every 4 hours is obligatory in all adults ≥50 years of age or those with impaired cell-mediated immunity.

---

Severe Intra-Abdominal Infections (IAI)

Complicated intra-abdominal infections (e.g., perforated viscus, secondary peritonitis, ischemic bowel, diverticular abscess) are polymicrobial processes involving enteric Gram-negative bacilli (Escherichia coli, Klebsiella pneumoniae, Proteus species), Gram-negative and Gram-positive anaerobes (Bacteroides fragilis, Peptostreptococcus), and Enterococci.

Empiric Regimens

• Severe Community-Acquired or Hospital-Acquired IAI:
  • Piperacillin-tazobactam 4.5 g IV every 6 hours administered as an extended 4-hour infusion (maximizes time above MIC against Pseudomonas and Enterobacterales).
  • Alternative (Cephalosporin-based): Cefepime 2 g IV every 8 hours PLUS Metronidazole 500 mg IV every 8 hours.
  • Septic Shock, High Local ESBL Prevalence, or Documented Colonization:
    • Meropenem 1 g IV every 8 hours (extended 3-hour infusion) or Imipenem-cilastatin 500 mg IV every 6 hours.

---

Necrotizing Soft Tissue Infections (NSTI / Necrotizing Fasciitis)

Necrotizing soft tissue infections (NSTIs) encompass necrotizing fasciitis, gas gangrene (clostridial myonecrosis), and Fournier gangrene (perineal necrotizing fasciitis). NSTIs are characterized by widespread fascial necrosis, thrombosis of subcutaneous microvasculature, and rapid systemic toxicity.

Clinical Presentation & Cardinal Signs

• Pain out of proportion to visible physical findings (the single most sensitive early physical indicator)
• Rapid progression of erythema and edema across marked clinical borders within hours
• Hard, wooden consistency of the subcutaneous tissues extending beyond the margin of erythema
• Cutaneous bullae (particularly violaceous or hemorrhagic bullae indicating deep tissue necrosis)
• Skin anesthesia (resulting from ischemia and necrosis of cutaneous nerve fibers)
• Palpable subcutaneous crepitus or soft tissue gas on radiologic imaging
• Severe septic shock with hemodynamic instability and unexplained elevated serum lactate

Microbiology

• Type I (Polymicrobial, ~70-80%): Synergy between aerobic Gram-negative bacilli (E. coli, Klebsiella), anaerobes (Bacteroides, Peptostreptococcus), and Gram-positive cocci (Staphylococcus, Enterococcus). Commonly seen in diabetic patients, immunocompromised hosts, and post-surgical wounds.
• Type II (Monomicrobial, ~20-30%): Group A Streptococcus (Streptococcus pyogenes), either alone or in combination with Staphylococcus aureus (including MRSA). Can occur in young, healthy individuals following minor blunt trauma, abrasions, or varicella infection. Monomicrobial clostridial myonecrosis (Clostridium perfringens) represents an additional lethal variant.

Emergency Pharmacotherapy & The Antitoxin Rationale

Immediate emergent surgical consultation for operative exploration and radical surgical debridement is the definitive primary therapy. Broad-spectrum empiric antimicrobial therapy must be initiated concurrently:

• Vancomycin: 15-20 mg/kg IV every 8-12 hours (loading dose 25-30 mg/kg) to provide rapid coverage for MRSA and resistant Gram-positive pathogens.
• Piperacillin-tazobactam: 4.5 g IV every 6 hours (or Meropenem 1 g IV every 8 hours) to cover broad Gram-negative bacilli and anaerobes.
• Clindamycin: 900 mg IV every 8 hours.

The Eagle Effect & Exotoxin Suppression Mechanics

Why is clindamycin mandatory when Group A Strep or Clostridium is susceptible to beta-lactams?

1. The Eagle Phenomenon (Inoculum Effect): Penicillins and beta-lactam antibiotics exert bactericidal activity by binding to penicillin-binding proteins (PBPs) during active bacterial cell wall synthesis. In deep necrotizing infections with high bacterial inocula (>10^7-10^8 CFU/g of tissue), bacteria enter a stationary growth phase. In this stationary phase, PBP expression is drastically down-regulated, rendering beta-lactams significantly less effective.
2. Exotoxin Suppression: Group A Streptococci and Clostridium species synthesize lethal exotoxins (streptococcal pyrogenic exotoxins SpeA, SpeB, SpeC; streptolysin O; and clostridial alpha-toxin and perfringolysin O). These toxins act as superantigens, bypassing normal antigen presentation, triggering massive non-specific T-cell activation, profound capillary permeability, and refractory vasodilatory septic shock.
3. Ribosomal Arrest: Clindamycin reversibly binds to the 50S ribosomal subunit of the bacterial ribosome, inhibiting peptidyl transferase and peptide chain elongation. By arresting protein translation, clindamycin rapidly halts the transcription and secretion of bacterial exotoxins independent of the bacterial inoculum size or growth phase.